H. pylori is best known as a stomach infection, but growing evidence links it to several liver conditions, including fatty liver disease, liver scarring (fibrosis), and even liver cancer. The connection isn’t direct in the way H. pylori damages the stomach lining. Instead, the bacterium appears to promote liver problems through chronic inflammation and metabolic changes that build up over time.
The Link Between H. Pylori and Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common liver condition in Western countries, affecting roughly 25% to 30% of the population. A 2023 meta-analysis found that people with H. pylori infection have a 27.5% higher chance of developing NAFLD compared to those without the infection. That makes H. pylori a meaningful, independent risk factor for fat accumulation in the liver.
The relationship goes beyond just having a fatty liver. One study found H. pylori DNA in nearly half of liver tissue samples from patients with NAFLD. And research has shown that nonalcoholic steatohepatitis (NASH), the more aggressive form of fatty liver that can lead to permanent damage, is more common in people who test positive for H. pylori than in those who don’t.
How a Stomach Bug Affects the Liver
H. pylori doesn’t typically travel to the liver and attack it directly. Instead, it triggers a cascade of low-grade, body-wide inflammation that eventually reaches the liver through the bloodstream. The infection ramps up production of inflammatory signaling molecules, particularly TNF-alpha and IL-6. These molecules interfere with how your body responds to insulin, creating a state of insulin resistance.
Insulin resistance is one of the central drivers of fatty liver disease. When your cells stop responding normally to insulin, your liver starts storing more fat than it should. At the same time, the persistent inflammation damages liver cells and promotes scarring. In people with H. pylori, both insulin resistance and TNF-alpha levels tend to be significantly higher, while adiponectin, a hormone that protects against inflammation, drops lower. This combination creates a metabolic environment where the liver steadily accumulates fat and sustains ongoing damage.
H. Pylori and Liver Fibrosis
Fibrosis, or scarring of the liver, is the stage where liver problems become more serious and harder to reverse. A study of patients with severe obesity found that those with H. pylori had significantly higher fibrosis scores across multiple measurement methods, including blood-based scoring systems and imaging. Liver biopsies confirmed the pattern: a higher incidence of fibrosis at every stage in the H. pylori-positive group.
This suggests the infection doesn’t just contribute to early-stage fat buildup. It may actively push the liver toward more advanced disease. Research tracking liver tissue from patients with chronic liver disease found H. pylori DNA in 17% of those with cirrhosis and 55% of those with liver cancer, with the bacterial DNA appearing more frequently at more advanced stages of disease.
Liver Cancer Risk
The most concerning finding involves hepatocellular carcinoma (HCC), the most common type of liver cancer. A systematic review and meta-analysis calculated that H. pylori infection is associated with nearly five times the odds of developing liver cancer compared to people without the infection. That’s a striking number, though it comes with important context.
The risk climbs dramatically when H. pylori infection overlaps with hepatitis C. People carrying both infections face roughly 14 times the odds of liver cancer. When researchers looked at H. pylori alone, without hepatitis C in the picture, the increased cancer risk largely disappeared. This suggests H. pylori may act as an accelerant for liver cancer rather than a standalone cause, worsening damage that’s already underway from other conditions like viral hepatitis.
Studies of liver tissue support this idea. In one analysis, H. pylori DNA was found in 90% of liver cancer tissue samples from patients who also had chronic liver disease, compared to just 4% of healthy control samples.
Connections to Bile Duct Disease
H. pylori has also been detected at high rates in people with cholestatic liver diseases, conditions where bile flow from the liver is impaired. In one study of patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), 80% tested positive for H. pylori. Among patients with non-cholestatic liver conditions or normal livers, only 4% were positive.
Researchers don’t believe H. pylori directly causes these autoimmune bile duct diseases. The evidence points more toward a triggering or aggravating role, where the infection provokes or worsens an immune response that was already predisposed to target the bile ducts.
Effects on Liver Enzyme Levels
If you have H. pylori, your routine blood work may show subtle signs of liver stress. A large cross-sectional study of the general population found that people with active H. pylori infection had higher ALT levels and were more likely to have elevated AST, one of the standard liver enzymes doctors check on blood panels. The H. pylori-positive group had about a 33% higher chance of having abnormally elevated AST compared to uninfected individuals.
These elevations tend to be mild, not the dramatic spikes seen in acute liver disease. But they reflect early liver injury that, left unchecked over years, can progress. In clinical studies, patients with unexplained mild liver enzyme elevations were tested for H. pylori, and a meaningful number turned out to be positive, with baseline ALT levels ranging from 44 to 79 IU/L.
Does Treating H. Pylori Help the Liver?
There’s encouraging, if still limited, evidence that eradicating H. pylori can improve liver-related markers. In patients with unexplained elevated liver enzymes and confirmed H. pylori infection, standard antibiotic treatment led to improvements in those enzyme levels. One case report documented improvement in both insulin resistance and fatty liver indices after successful H. pylori eradication, reinforcing the idea that the infection was actively contributing to the liver problem rather than just coexisting with it.
These findings don’t mean that treating H. pylori will reverse established cirrhosis or cure fatty liver disease. The liver damage involves multiple factors, and H. pylori is one contributor among many. But removing the infection appears to reduce at least one source of chronic inflammatory stress on the liver, which may slow progression or improve metabolic function, particularly in the earlier stages of disease.